A combination of a diabetes drug and a high blood pressure medication may effectively treat all symptoms of postmenopausal polycystic ovary syndrome (PCOS). The findings will be presented today at the American Physiological Society’s (APS) Cardiovascular, Renal and Metabolic Diseases: Sex-Specific Implications for Physiology conference in Knoxville, Tenn.
PCOS is a condition in which a woman has higher-than-normal androgen (male sex hormone) levels. This hormonal imbalance leads to the development of ovarian cysts, as well as a collection of symptoms, including obesity, insulin resistance, high blood pressure and high cholesterol. These characteristics together are commonly referred to as metabolic syndrome. PCOS can contribute to fertility problems during the reproductive years, and the symptoms of metabolic syndrome often linger throughout a woman’s life, even after menopause.
Previous research has shown that liraglutide—a medication used to treat type 2 diabetes—lowers blood pressure in women without PCOS. Whether or not liraglutide lowers blood pressure in postmenopausal women with PCOS is still unknown. However, the drug promotes significant weight loss in childbearing-age women with PCOS. Liraglutide has also been found to reduce insulin resistance and blood pressure in rat models of reproductive-age PCOS.
Researchers from the University of Mississippi Medical Center studied a rat model of postmenopausal PCOS. The animals received liraglutide alone for three weeks, followed by separate one-week regimens of the renin angiotensin system (RAS) blocker enalapril and a drug cocktail of liraglutide combined with enalapril. Enalapril treats high blood pressure by blocking activation of the RAS, a group of hormones that acts as a main regulator of blood pressure.
Source: Read Full Article